May 14, 2024 7:18am

After careful examination of the sector and breathe trends, I am cautious. Having lived through the rise and multiple declines of “our” universe’s stock price, investors must be better informed on what fluctuating markets can do to an equity, or what impact inflation data or earnings expectations can have.

Earnings: Precigen (PGEN) and Generation Bio (GBIO

Markets awaits week's producer price index and the consumer price index for signs that U.S. inflation has resumed its downward trend toward the Fed's 2% target rate.

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi

 

Tuesday: The pre-open Dow futures are UP +0.04% or (+13 points), the S&P futures are UP +0.03% or (+1 points) as the Nasdaq futures are UP +0.02% or (+4 points)

Stock futures flickered near the flatline, Tuesday, 5/14/24  

European stocks were flat,

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed mixed Monday as traders grappled with rising inflation expectations ahead of key reports due later in the week.

Economic Data Docket: Producer Price Index, month-over-month, April (+0.3% expected, +0.2% previously); PPI, year-over-year, April (+2.2% expected, 2.1% previously); NFIB Small Business Optimism, April (88.2 expected, 88.5 previously);

 

Monday night’s RegMed Investors (RMi) Closing Bell: “up and some astray as sector speculative rises. Even as inflation expectations increase.” … https://www.regmedinvestors.com/articles/13458

 

Q2/24:  May – 6 positive and 3 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Yet again, I am passing on forecasting the daily indications is focused on inflation-oriented PPI and NFIB Small Business Optimism report “numbers” the aftermarket fluctuated as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE: The Q1/24 earnings season is winding down as 26 of my 35 have reported, but investors will see a few more reports this week

After hours reporting:

  • Harvard Apparatus RT (OTCQB: HRGN) reported a Q1/24 net loss of -$2 M or -0.15 per share with a cash position of $300 K (from $500K convertible debt from CEO) and a runway until Q4/24 having raised $1.5 M PIPE, BIG issue: current liabilities 2.24 K>
  • Funny, how they rushed-out their Q1 and PIPE news as I reported it in the a.m. – scooped!
  • It’s also very telling rejection by U.S. investors and capital markets with the ultra-heavy reliance of Chinese investors which have been stepped-on (again)?

 

Pick your poison, trade any ups, buy into some bottoms, build cash position; as buying the lows - they can eventually be the overbought through unbridled speculation and then trade again.

  • On Monday, the Dow moved down 0.2% and the S&P 500 lost less than 0.1% while the Nasdaq composite gained 0.3%.

 

An appropriate quote, “CPI and PPI reports will be important to investors, there's been so much discussion about the consumer. Is the consumer tapped out? And can the consumer still afford to spend? CPI is going to encapsulate a lot of that." < Paul Nolte, senior wealth adviser and market strategist for Murphy & Sylvest in Elmhurst, Illinois>

 

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

  • Investors must eye-ball earnings results, runways, and forecasts. Missed EPS and revenue indications usually signify the changing landscape of short and near-term prospects and trends.
  • With this in mind, missed estimates reveal a sign of pessimism about sector company's share pricing outlook other than possible pop tarts of clinical results or potential partnership or acquisition actions.
  • My on-going theses suggests that estimates have a direct relationship with upcoming stock price performance.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.